Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 534 (LINC00534) is a human long non-coding RNA (lncRNA), meaning it is a functional RNA molecule longer than 200 nucleotides that is not translated into protein. LINC00534 has been shown to be upregulated in breast cancer and acts as a molecular sponge for specific microRNAs, especially miR-139-5p, promoting cell proliferation, migration, and invasion, and contributing to tumor progression and metastasis. In trophoblast cells, LINC00534 inhibits cell proliferation and migration while promoting apoptosis, likely through a miRNA-mediated mechanism involving PTEN and the PI3K/AKT pathway, with implications for placental development and preeclampsia. LINC00534 may thus serve as a prognostic biomarker and a putative therapeutic target in various diseases, though no drugs or therapeutic interventions currently target it directly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 534 (LINC00534).